hydralazine

hydralazine
Name	Hydralazine
Routes of administration	Oral, intravenous, intramuscular
ATC prefix	C02
ATC suffix	DB01
Legal status	Prescription only
CAS number	304-20-1
PubChem	3639

hydralazine is a vasodilator used primarily in the management of hypertension and heart failure. It acts on vascular smooth muscle to reduce systemic vascular resistance, often employed when other antihypertensive agents are inadequate or contraindicated. Its clinical role has evolved alongside diuretics, beta blockers, and renin–angiotensin agents as cardiovascular therapeutics have advanced.

Medical uses

Hydralazine is indicated for treatment of essential hypertension when monotherapy is insufficient and for severe hypertension in combination with other agents. It is used in acute hypertensive emergencies in hospital settings, including hypertensive crises associated with pregnancy-related conditions such as preeclampsia and eclampsia when rapid afterload reduction is required. In chronic heart failure, hydralazine combined with isosorbide dinitrate has proven benefit in select populations and was highlighted in trials influencing practice guidelines in management of congestive heart failure and outcomes in African American cohorts. It is sometimes used perioperatively to manage blood pressure in patients undergoing procedures like cardiac surgery or other high-risk operations.

Contraindications and precautions

Hydralazine is contraindicated in patients with known hypersensitivity to the agent and in those with severe coronary artery disease such as unstable myocardial infarction where reflex tachycardia could worsen ischemia. Caution is advised in patients with a history of connective tissue disorders including systemic lupus erythematosus because of drug-induced lupus-like syndromes and in those with mitral valve rheumatic disease such as prior rheumatic fever causing mitral regurgitation where increased cardiac output may exacerbate regurgitant lesions. Use with care in pregnancy-related contexts: although employed in preeclampsia management, it requires obstetric consultation and monitoring. Concurrent use with other vasodilators or sympathetic stimulants used in intensive care settings such as agents administered during anesthesia necessitates close hemodynamic surveillance.

Adverse effects

Common adverse effects include headache, flushing, tachycardia, and palpitations due to peripheral vasodilation; these mirror findings observed with other rapid-acting vasodilators used in acute care and cardiovascular trials. Long-term therapy can precipitate a drug-induced lupus-like syndrome characterized by arthralgia, myalgia, fever, and serologic markers similar to those seen in systemic lupus erythematosus; this adverse event was described in pharmacovigilance reports and cohort studies. Less common events include peripheral neuropathy, skin eruptions, and gastrointestinal upset. Rare but serious complications include ischemic cardiac events in patients with underlying coronary artery disease from reflex sympathetic activation and precipitous hypotension during combined use with other antihypertensives or in volume-depleted states.

Pharmacology

Hydralazine directly relaxes arteriolar smooth muscle through mechanisms that include modulation of intracellular calcium handling and opening of potassium channels in vascular smooth muscle cells identified in cellular physiology studies. It reduces afterload by decreasing systemic vascular resistance while preserving or increasing cardiac output; this hemodynamic profile contrasts with agents that primarily affect venous capacitance or neurohormonal axes targeted by drugs studied in trials by institutions such as National Institutes of Health and clinical networks. Reflex sympathetic activation increases heart rate and renin secretion, often necessitating concomitant use of beta-adrenergic blockers or renin–angiotensin inhibitors; combinations were evaluated in landmark multicenter trials influencing guidelines issued by bodies like the American Heart Association and European Society of Cardiology.

Pharmacokinetics

After oral administration, hydralazine demonstrates variable bioavailability due to first-pass hepatic metabolism, with plasma concentrations affected by genetic polymorphisms in hepatic acetylation pathways studied in pharmacogenetics research at centers such as Mayo Clinic and Johns Hopkins Hospital. It is metabolized primarily by acetylation and conjugation in the liver and eliminated in urine; slow and fast acetylator phenotypes alter half-life and systemic exposure, an observation first characterized in pharmacology laboratories associated with universities like Harvard Medical School and Stanford University. Plasma protein binding is modest and volume of distribution reflects distribution into peripheral tissues examined in clinical pharmacology trials.

Dosage and administration

Oral dosing typically begins at low doses with gradual titration to minimize adverse effects; typical initiation regimens described in prescribing compendia and hospital formularies start at low milligram doses given two to four times daily with adjustment based on blood pressure response and tolerability. Intravenous administration is reserved for hypertensive emergencies and supervised inpatient settings such as intensive care units in tertiary hospitals including Mayo Clinic and university medical centers where continuous hemodynamic monitoring is available. In heart failure regimens where combined therapy is indicated, dosing schedules align with protocols from landmark trials and practice guidelines promulgated by organizations such as the American College of Cardiology.

History and society

Hydralazine was synthesized in the early 20th century and entered clinical use mid-century during an era of expanding cardiovascular pharmacotherapy; its adoption and study occurred in academic centers and industry research programs across North America, Europe, and elsewhere. Its role in combination therapy for heart failure, notably with isosorbide dinitrate, was established in randomized clinical trials that informed guideline recommendations and influenced care in diverse populations including studies led by investigators affiliated with organizations like the National Heart, Lung, and Blood Institute and academic consortia. Over time, shifts in prescribing patterns followed the development and widespread adoption of ACE inhibitors, angiotensin II receptor blockers, and newer heart failure agents promoted by clinical trials and guideline updates from groups such as the European Society of Cardiology. Hydralazine remains included in formularies and essential medicine lists in various health systems and is the subject of ongoing pharmacogenomic and clinical outcomes research at institutions like University of California, San Francisco and global health research centers.

Category:Antihypertensive agents